[Recommendations for statin therapy in the elderly].
Elderly patients are significantly less likely to receive statins than younger patients possibly because of doubts regarding compliance or concerns regarding the increased likelihood of adverse events and drug interactions. Poor compliance can be expected especially in patients suffering from dementia or depression as well as those whose stage of cardiovascular disease exhibits few symptoms. On the other hand, the clinical significance of CHD events is high in the elderly, and 80% of coronary deaths occur in patients aged over 65 years. The average statistical life expectancy of elderly and old patients is often underestimated. The HPS and PROSPER studies showed that statins reduce mortality and morbidity even in very elderly individuals with a high global cardiovascular risk and/or CAD. Patients up to the age of 79 years should be treated according to the same guidelines as younger patients. Statin therapy should only be considered for patients aged 80 years and older who are at a very high risk for cardiovascular events.
Döser
S
S
IV. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Ruprecht-Karls-Universität Heidelberg.
März
W
W
Reinecke
M-F
MF
Ringleb
P
P
Schultz
A
A
Schwandt
P
P
Becker
H J
HJ
Bönner
G
G
Buerke
M
M
Diener
H C
HC
Gohlke
H
H
Keil
U
U
Ringelstein
E B
EB
Steinmetz
A
A
Gladisch
R
R
Wehling
M
M
D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality; D004363:Drug Utilization / Q000639:trends; D005260:Female; D005544:Forecasting; D005858:Germany; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000401:mortality; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors